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Abstract
MicroRNAs (miRNAs) participate in crucial biological processes, and it is now evident that miRNA alterations are involved in
the progression of human cancers. Recent studies on miRNA profiling performed with cloning suggest that sequencing is
useful for the detection of novel miRNAs, modifications, and precise compositions and that miRNA expression levels
calculated by clone count are reproducible. Here we focus on sequencing of miRNA to obtain a comprehensive profile and
characterization of these transcriptomes as they relate to human liver. Sequencing using 454 sequencing and conventional
cloning from 22 pair of HCC and adjacent normal liver (ANL) and 3 HCC cell lines identified reliable reads of more than
314000 miRNAs from HCC and more than 268000 from ANL for registered human miRNAs. Computational bioinformatics
identified 7 novel miRNAs with high conservation, 15 novel opposite miRNAs, and 3 novel antisense miRNAs. Moreover
sequencing can detect miRNA modifications including adenosine-to-inosine editing in miR-376 families. Expression profiling
using clone count analysis was used to identify miRNAs that are expressed aberrantly in liver cancer including miR-122, miR-
21, and miR-34a. Furthermore, sequencing-based miRNA clustering, but not individual miRNA, detects high risk patients
who have high potentials for early tumor recurrence after liver surgery (P=0.006), and which is the only significant variable
among pathological and clinical and variables (P=0,022). We believe that the combination of sequencing and
bioinformatics will accelerate the discovery of novel miRNAs and biomarkers involved in human liver cancer.
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Introduction
Hepatocellular carcinoma (HCC) ranks in prevalence and
mortality among the top 10 cancers worldwide [1,2,3]. The
estimated number of new cases of HCC had risen to 564 300
and 548 600 people with HCC had died, representing 97.2%
of persons with this diagnosis. The WHO estimates that 2
billion people worldwide have been infected with the hepatitis
B virus (HBV), which is the most common cause of HCC, and
that 350 million people have chronic HBV infection. As the
current therapeutic options for HCC patients are limited, there
is an urgent need to analyze the molecular oncogenic
mechanisms in order to determine novel targets for specific
systemic therapy and to detect novel biomarkers for early
diagnosis.
MicroRNAs (miRNAs) participate in crucial biological pro-
cesses, including development, differentiation, apoptosis, and
proliferation [4,5] through imperfect pairing with target messen-
ger RNAs (mRNAs) of protein-coding genes and transcriptional
or post-transcriptional regulation of their expression [6,7].
Approaches to miRNA detection, such as parallel sequencing
technologies may replace conventional sequencing[8]. The GS
454 technology can produce a similar number of longer (100–
150-nucleotides (nt)) sequence reads in a single analysis run[9],
with the advantage that this method can derive the complete
sequence of the mature miRNA. Moreover, recent studies on
miRNA profiling performed with cloning techniques suggest that
sequencing methods are suitable for the detection of novel
miRNAs, modifications, and precise compositions, and that
cloning frequencies calculated by clone count analysis strongly
correlate with the concentrations measured by Northern blotting,
and are reproducible. The achievement of comprehensive
profiling of miRNA in human diseases requires exhaustive
qualitative and quantitative analyses. Here we focused on the
sequencing method to profile and characterize miRNA tran-
scriptomes in the liver. This serves as a critical step in clarifying
the functional significance of specific miRNAs as they relate to
HCC.
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Study populations, liver tissues, and cell lines
The study material comprised 22 pairs of HBV-associated HCC
liver samples obtained from patients undergoing liver surgery at
the Department of Liver Surgery, Nippon Medical School
Hospital (Table S1). The study protocol was approved by the
Human Ethics Committee of the Nippon Medical School and the
Research Ethics Committee of the Nippon Medical School.
Patients who signed on the written informed consent form were
enrolled in this study. All of the patients were positive for
circulating hepatitis B surface antigen (HBsAg) or antibody to
hepatitis B core antigen (anti-HBc) and were negative for antibody
to hepatitis C virus (anti-HCV), autoimmune liver disease, primary
biliary cirrhosis, primary sclerosing cholangitis, and concomitant
inflammatory connective tissue disorder. None of the patients had
past or present medical histories of alcohol abuse or long-term
consumption of corticosteroids or tamoxifen. Normal liver tissues
adjacent to the cancer were used as controls. In addition, six
normal liver samples devoid of any cancer were included in the
study. The three human HCC cell lines, JHH-7, HuH-1, PLC/
PRF/5, Hep3B which were infected with HBV, were obtained
from the Cancer Cell Repository at Tohoku University, Sendai,
Japan. All of the cell lines were maintained for less than 6 months
from when the suppliers sent them and were handled as
recommended by the suppliers at 37uC and 5% CO2 in a
humidified incubator.
Conventional cloning and 454 sequencing of miRNAs
We cloned small RNA by a modification of the published
miRNA cloning protocol[10]. In brief, total RNA samples were
extracted using ISOGEN (Nippon Gene, Tokyo, Japan), separated
in a denaturing polyacrylamide gel, and the 18–24 nt fraction was
recovered. Next, 59- and 39-adapters were ligated to the RNAs and
RT-PCR was carried out. Amplification of the cDNA fragments
was obtained by two consecutive rounds of PCR. Specific
restriction enzyme digestion of the adaptors allowed for con-
catemerization of the cDNA into larger fragments. These
fragments were then cloned into a vector to create a cDNA
library. Concatemerization increases the length of informative
sequences obtainable from each clone. The sequences were
compared to human DNA to determine the genomic origin of
the small RNA. For expression analysis, the RNA sequences from
the clones were annotated and normalized per 1 000 reads. For
454 analysis, combined cDNA from HCC samples positive for
hepatitis surface antigen (n=18) was compared to combined
cDNA from adjacent normal liver (ANL) samples (n=18)
(Figure 1).
Bioinformatics analysis of the sequence data
Comparing the cloned sequences with those of known
RNAs. The small RNA sequences were analyzed for homology
with known RNAs, including miRNA, piwi-interacting (pi) RNA,
rRNA, tRNA, small nuclear (sn) RNA, small nucleolar (sno) RNA,
and mRNA, and human genomic DNA sequences. The databases
used were: miRNA (mature- and pre-), Sanger Database.; piRNA,
the NCBI Entrez Nucleotide database; rRNA, the European
ribosomal RNA database; tRNA, the Genomic tRNA database;
sn/snoRNA, RNAdb and NONCODE; mRNA, NCBI Reference
Sequence; and human genomic sequences, the UCSC Genome
Bioinformatics Site. In our searches, we defined the cloned
sequencing results that had higher than 90% homology as valid if
they met our criteria for sequence error, erroneous PCR
amplification, and 39- and 59-end variations. Clones that shared
100% homology with human genomic DNA but did not match
known RNAs when compared to the above databases were termed
novel miRNA candidates and were subjected to further analysis.
Secondary structure analysis. The two-dimensional
precursor miRNA (pre-miRNA) configurations of our novel
miRNA candidates were predicted according to the method
described previously [11] with some modifications. Briefly, 196-nt
of genomic sequence was added to the candidate sequences (88-nt
at each end). Each candidate sequence was divided into 110-nt
windows and subjected to two-dimensional analysis along its entire
length, using the RNAfold software (Vienna RNA Secondary
Structure Package[12]). The configurations that had the lowest
free energy and that had a high conservation (described below)
and met the following criteria were termed novel miRNAs: (a)
contained a stem-loop configuration; (b) cloned mature miRNA
sequence portion consisted of more than 16-nt in its double-
stranded region; (c) the loop contained fewer than 20-nt; (d) the
internal loop contained fewer than 10-nt; and (e) the bulge
contained fewer than 5-nt. Furthermore, novel sequences with
overlapping positions in the genome were grouped together. Novel
antisense miRNAs are defined with above criteria (a)-(e) but
without conservation score if they are coded in same chromosomal
region.
Determination of hairpin conservation. We classified all
the candidate miRNAs using the PhastCon database at the
University of California at Santa Cruz[13,14]. This database has
scores for each nucleotide in the human genome relative to its
degree of conservation when compared to nucleotides in the
armadillo, bush baby, cat, chicken, chimpanzee, cow, dog,
elephant, frog, fugu, guinea pig, hedgehog, horse, lizard,
medaka, mouse, opossum, platypus, rabbit, rat, rhesus monkey,
shrew, stickleback, tenrec, tetraodon, tree shrew, and zebrafish.
The algorithm is based on a phylogenetic hidden Markov model
that uses best-in-genome pairwise alignment for each species
(based on BLASTZ), followed by multiple alignment of the twenty
eight genomes. A hairpin was defined as conserved if the average
PhastCon conservation score over the 28 species for any 15-nt
sequence in the hairpin stem was at least 0.8[15].
Hierarchical clustering of miRNA expression. All the 53
samples were analyzed - 22 HCC serologically positive for HBsAg,
22 ANL, 3 HBsAg positive cancer cell lines, and 6 normal liver
tissues clustered using miRNA cloning. Clustering analysis was
performed with cloned mature miRNAs. Mature miRNAs that
were expressed in fewer than 25% of the samples were not
subjected to analysis. The samples are listed in the columns, and
the miRNAs are listed in the rows.
Gene ontology analysis. The predicted targets of hsa-miR-
21, hsa-miR-34a, and hsa-miR-122 were determined using the
miRBase Targets Beta version 1.0 and Target Scan programs and
analyzed with respect to overrepresentation within different
biological grouping categories, including gene ontology (GO).
The level of overrepresentation was measured using Fisher’s exact
test in a 262 contingency table for each GO term (whether a gene
is in the given list or not versus whether this gene is associated with
a GO term or not). The Fisher’s exact test P values were calculated
for each term in each GO and ranked from smallest to highest
values, to estimate the statistical significance and priority for each
term.
Detection and determination of RNA modification
sites. Two independent measurements (conventional cloning
method and 454 sequencing) were performed, generating identical
values. For miR-376c, miR-376a, miR-34a, miR-503, miR-21,
and miR-122, the RNA modifications were detected using both
methods, and the possibility of a single nucleotide polymorphism
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the public database OncoDb HCC. Adenosine (A)-to-inosine (I)
editing was identified as a novel guanosine (G) peak and a drop in
peak height at the As in a cDNA sequence relative to the
equivalent peak in the matching genomic DNA sequence. X-to-Y
editing was identified as a novel Y peak and a drop in peak height
at the Xs. The drop in peak height between the DNA reference
trace and the cDNA trace at the modified nucleotide is reported as
a percentage of the peak height in the genomic DNA reference
trace. For each modified miRNA, the mean extent of modification
for each tissue is calculated from all the cDNA sequences obtained
from that tissue.
PCR analysis of novel miRNAs. After bioinformatic
analysis of the sequence data, we further validated novel
miRNAs by PCR-based miRNA detection [16]. Briefly, small
RNAs from Hep3B cell line were isolated using the mirVana
TM
miRNA isolation kit (Ambion). Small RNA samples were
polyadenylated with Poly (A) Tailing Kit (Ambion) and were
purified with Acid-Phenol:Chloroform and with filter cartridge
provided in the mirVana Probe & Marker Kit (Ambion). To
generate a small RNA cDNA library, tailed RNA were reverse
transcripted using RTQ primer [16] and the samples were
purified using the QIAquick spin PCR purification kit (QIAGEN).
A small RNA-specific primer and a universal reverse primer
(Table S2), RTQ-UNIr [16], were used for amplification of each
of the small RNAs. The PCR products were analyzed on a 12%
polyacrylamide gel. The primers for the human GAPDH were
used for negative control.
Clinicopathologic variables
The clinicopathologic variables were selected according to the
general rules for the clinical and pathologic study of primary liver
cancers[17], i.e., TNM stage[18], histological differentiation,
growth type, capsule formation (fc), capsule invasion (fc-inf),
septum formation (sf), serosa invasion (s), portal vein invasion (vp),
venous invasion (vv), arterial invasion (a), bile duct invasion (b),
and intrahepatic metastasis (im). Other factors studied included
the patient’s age, gender, and hepatitis virus.
Statistical methods
A P value of ,0.05 was considered statistically significant, and
all tests were two-tailed. All interval values are expressed as mean
Figure 1. Overview algorithm of the miRNA analysis in this study.
* Filtering indicates filtering of t/r/sn/sno/m/piRNAs. HCC, hepatocellular
carcinoma; ANL, adjacent normal liver; cDNA, complementary DNA; CGH, comparative genomic hybridization.
doi:10.1371/journal.pone.0015304.g001
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calculated by the paired Student t test. For categorical compar-
isons of the data, the x
2 test or Fisher’s exact test was used. To
detect miRNAs with significant differences between HCC and
ANL, we used SAM, which is a statistical technique for finding
significant genes originally in a set of microarray experiments.[19]
SAM computes a statistic di for each gene i, measuring the strength
of the relationship between miRNA gene expression and the
response variable. It uses repeated permutations of the data to
determine whether the expression of any specific gene is
significantly related to the response. We determined the cut-off
for significance using a tuning parameter delta, chosen on the basis
of a false-positive rate of zero. The array data was used to
construct receiver-operating-characteristic curves by plotting the
relationships of the true positives (sensitivity) and false positives (1-
specificity). For survival analysis, we computed the statistical
significance for each variable based on a Cox proportional hazards
regression model. The Kaplan-Meier method was used to estimate
the patient survival and recurrence curve, and the log-rank test
was used to compare the subgroups. A multiple Cox proportional
hazards regression model was used to investigate the multiple
variables individually for a possible association with survival. We
introduced all of the pathologic variables and age and gender
(Table S1) into the Cox regression model.
Accession Numbers
The reported novel miRNAs we have deposited with DDBJ
under accession codes as indicated.
Websites for database used in this manuscript
NCBI Entrez Nucleotide database, http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db=Nucleotide; European ribosomal RNA
database, http://psb.ugent.be/rRNA/; Genomic tRNA database,
http://lowelab.ucsc.edu/GtRNAdb/; RNAdb, http://research.
imb.uq.edu.au/randb/; NONCODE, http://www.bioinfo.org.
cn/NONCODE/; NCBI Reference Sequence, ftp://ftp.ncbi.nih.
gov/refseq/; UCSC Genome Bioinformatics Site, http://genome.
ucsc.edu; OncoDb HCC, http://oncodb.hcc.ibms.sinica.edu.tw/
index.
Results
Qualitative analysis of miRNAs using sequencing and
prediction of novel and various coding of precursor
miRNAs in human liver
To obtain the miRNA gene expression profiles of liver tissues
from patients with HBV associated HCC (Table S1), we
combined conventional cloning with GS 454 sequencing technol-
ogy (Figure 1). We introduced concatemerization to increase the
length of the informative sequence obtained from each sequence
read. Software programs and databases were used for the
identification and annotation of miRNAs. We identified more
than 314 000 reliable reads from HCC and more than 268 000
from ANL for human miRNAs registered in miRBase (Table S3).
A high percentage (approximately 80%) of the clone reads
(.400 000) was matched to annotated human miRNA sequences
(Table S4). A low percentage of the clone reads matched
annotated m/t/r/sn/snoRNA. Unexpectedly, more than 4 400
(0.76%) reads were annotated as piRNA.
Based on these criteria, a scan of all the novel miRNA
candidates (.250) identified 10 novel precursors with evolution-
arily high conservation, representing putative 10 novel mature
miRNAs (Figure 2A and Table S5). Fifteen novel opposite
miRNAs (defined as miRNAs cloned from the other arm of
precursors from which known miRNAs have been cloned) were
identified from the annotated miRNAs (Table S6). And also three
novel antisense miRNAs were identified from the annotated
miRNAs (Figure 2B and Table S5). Although opposite
miRNAs are inferred to exist for all miRNAs, some miRNAs
(e.g., hsa-miR-503) with many clone reads have no opposite
sequence. Unexpectedly, bioinformatics analysis and secondary
structure predictions of the novel miRNA candidates allow the 7c
precursor to produce three non-overlapping mature miRNAs from
the 59-pole, 39-pole, and loop, respectively (Figure 2C). In the
present study, the highly conserved miRNAs of the let-7 family
exhibited opposite miRNAs, with the exception of let-7a-2, and
the sequences were highly similar to each other, generating six
distinct seeds (i.e., nt 1 or nt 2–8 of the mature miRNA) (Figure
S1), thereby supporting our results. We then probed to confirm
whether these 10 candidates for novel miRNA could be detected
using PCR-based small RNA detection method. Seven of 10
candidates were specifically detected by the method, which
indicates that these candidates were indeed novel miRNAs
(Figure 2D). Specific bands for the other candidates like
AB372776 and band for the GAPDH were undetectable
(Figure 2D).
Detection of various RNA modifications in mature
miRNAs
A recent study has reported tissue-specific editing of miR-376
cluster members and the expression of edited mature miR-376
RNAs in certain tissues [20]. Next, we focused on the sequence
compositions of cloned mature miRNAs. In general, these analyses
indicate that for a given mature miRNA there are many sequence
compositions. The 59-proximal end sequence (+1) was almost
always conserved. In contrast, the 39-end sequence (1–3 nt)
showed many variations, presumably resulting from incomplete
participation of RNase III in the process of biogenesis. Thus, in
principle, the seed sequences are highly conserved in these clones
(.98%). Scanning of the sequence compositions revealed that
certain miRNAs were predominantly substituted at specific
positions, even at the seed positions (Figure 3A). First, in miR-
376c and miR-376a, members of miR-376 cluster, specific
adenosine (A) residues in the seed sequence (+6 site) were detected
as guanosine (G) in the sequencing chromatogram, which suggests
adenosine to inosine (I) editing [20]. Overall, 31% and 50% of the
miR-376c and 86% and 50% of the miR-376a were expressed as
the edited form in HCC and ANL, respectively. Second, a
component of the p53 tumor suppressor network, miR-34b*,
belongs to an evolutionarily conserved miR-34 family (miR-34a-c),
with single, recognizable orthologues in several invertebrate
species[21]. The miR-34b* is not conserved at the +10 position
between humans and rodents. Of particular interest, almost all the
miR34b* forms are expressed with CRA editing at the +10
position (HCC, 96%; ANL, 100%) in the liver, resulting in the
same sequence as those observed in the mouse and rat. In contrast,
no modifications were detected in miR-34a and miR-34c. Third,
74% and 78% of miR-503 expressed URA at the +17 position in
the modified forms in HCC and ANL, respectively.
Further investigation of the mature miRNAs at positions +1t o
+18 (excluding the 39-variable sequences) revealed that, although
notpredominant (,5%), modified sequenceswerepresent inalmost
all the miRNAs. In the analysis of the top 50 (Table S7) sequences
of the mature miR-122 and miR-21, ARI modifications, URC,
GRA, URA, and CRU modifications were observed, as evidenced
bythepresenceofa single peak (Figure3B).URCediting hasbeen
suggested only for primary miRNA (pri-miRNAs) [22], and other
modification types have not been reported for pri-mRNAs and
Sequencing-Based miRNA Transcriptome in the Liver
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ARI (+2a n d+7) and URC (+1, +5, +6, +8) at the seed sequence
were detected, whereas in the mature miR-122, ARI editing was
notdetected (Figure3B,FigureS2).Theseresultsstronglysuggest
that these modifications should be considered as confounding
factors for accurate and precise miRNA expression profiles using
hybridization-based methods.
Detection of aberrant expressing miRNAs in human liver
cancers using clone count analysis
It has become evident that miRNA alterations are involved in
the initiation and progression of human cancer[23,24,25].
Using sequence-based methods, we set out to determine the
expression patterns of miRNAs, including novel miRNAs, across
a panel of samples representing human HBV associated HCC.
The samples from malignant and benign liver specimen were
clustered together using miRNA cloning, which confirms the
ability to distinguish HCC from ANL (Figure 4A). The cancer
cell lines showed similar expression profiles and were placed in
cluster 1. Cluster 2 contained all the HCC samples with the
distinct characteristics of high miR-21 (.250) expression
(Figure 4B). When the clustering results were analyzed without
taking into consideration the modified forms, the profiles were
different from each other (Figure 4C). To evaluate statistically
Figure 2. Qualitative analysis of miRNAs in the human liver. (A)–(C) Secondary structure and genome location of novel miRNAs (A), novel
antisense miRNA (B) and pre- let7C (C). The cloned novel and known mature miRNA sequences are indicated in blue or red, respectively. (D) Analysis
of novel miRNAs using semiquantitative PCR. A representative gel picture shows the expression of novel miRNAs. GAPDH was used as a negative
control. The numbers following AB (e.g., AB 372796) are accession codes we have been depositing with DDBJ. (See Materials and Methods).
doi:10.1371/journal.pone.0015304.g002
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serologically positive for HBsAg, the corresponding 18 ANL
samples, and all the miRNAs listed in Figure 4A were
introduced into student’s-t test and SAM analysis (Table S8).
In the student’s-t analysis, seven miRNA genes in HCC had
statistically higher expression levels and five had lower
expression levels than those in ANL. Only the expression levels
of the nonmodified form (not the modified form or the
nonmodified plus modified form) of miR-503 were confirmed
to be significantly different between HCC and ANL (P=0.025).
In the SAM analysis, two miRNAs were upregulated: (a)m i R - 2 1 ,
which is overexpressed in many kinds of cancers and accelerates
cell migration and invasion thorough phosphatase and tensin
homolog (PTEN) in HCC [26]; and (b) miR-34a, which is a
component of the p53 tumor suppressor network. Furthermore,
miR-122 was downregulated, and it has been previously
reported to be specifically expressed and highly abundant in
human liver and required for the replication of HCV RNA[27].
To gain insight into the potential biological impact of aberrant
miRNA expression in HCC, we identified Gene Ontology (GO)
terms for the cellular process, molecular function, and cellular
component categories[28], which were overrepresented in the
predicted targets of aberrantly expressed miRNAs as compared
with all the Ensembl genes (Figure 5). For the three aberrantly
expressed miRNAs, analysis of overrepresented GO terms
associated with the predicted targets of stronger- and weaker-
expressing miRNAs revealed distinct differences.
Potentials of miRNA sequencing and bioinformatics for
detecting clinical biomarkers
These data prompted the hypothesis that the miRNAs which
are aberrantly expressed in HCC could be used as diagnostic
biomarkers for HCC. As previously reported, the expression levels
of miR-21 in HCC is significantly increased, whereas that of miR-
122 is decreased. Thus we next studied whether expression levels
of these miRNAs including miR-34a calculated with sequencing
can also have potentials as clinical biomarkers. Receiver-
operating-characteristic curves were constructed for the prediction
of HCC (Figure 6A). From the analyses of the area under the
curve, miR-21 and miR-122 appear to have potential as
biomarkers for the prediction of HCC. The miR-21 cut-off point
of 100 and the miR-122 cut-off point of 250 were the most reliable
cut-off points in identifying ANL from HCC (Table S9). Having
determined that the miRNAs expression levels distinguished
tumors from non-tumors, we then considered whether miRNAs
could be used as biomarkers for the clinical course of disease,
particularly as predictors of survival and cancer recurrence after
liver surgery. The individual miRNA Cluster 2 consisted
exclusively of malignant tissues and had the prominent character-
istic of miR-21 expression (.250), which was about 2-fold higher
than the most reliable diagnostic cut-off point for HCC. Using the
Kaplan-Meier test, and including the patients with historic HBV
infection (n=22), the patients in cluster 2 were found to have
significantly (P=0.0006) earlier recurrence time (mean, 7.6
months) than the other patients (mean, 57.6 mo) (Figure 6B,
Figure 3. RNA modifications of mature miRNAs in the human liver. (A) Sequence analysis with chromatogram of mature miRNAs for which
the modified forms are predominantly expressed in the liver. Modified miR-376c, miR-376a, miR-34b*, and miR-503 are detected by RT-PCR and
conventional cloning. An ARI modification is shown as ARG, and URA editing is shown as TRA. The horizontal bars under the chromatograms
indicate the miRNA site with the 59-proximal seed region marked by a thick white bar. Nucleotide substitutions are highlighted in black. The modified
sites are numbered with the 59-end of the mature miRNA sequence designated as +1. The vertical bars located below each peak of the
chromatogram are quality values bars which indicate the veracity of each base call. A horizontal line is placed across the quality bars. The bars above
this line indicate base calls that have a more than 99% probability of being correct. The bars underneath this line have a less than 99% probability of
being correct. The frequency of modified and non-modified clone reads for HCC and ANL from the 454 sequencer are charted in the bar graphs
below the chromatograms. (B) Sequence analysis with chromatogram of mature miR-21, in which ARI or URC modification occurs in the 59-proximal
seed sequence. The miRNA site, 59-seed region, and base call quality value bars are as described above.
doi:10.1371/journal.pone.0015304.g003
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predict patients’ survival nor cancer recurrence after surgery (data
not shown). In accordance with the cancer recurrence rate,
although not statistically significant, the Kaplan-Meier analysis
revealed that the patients in cluster 2 had a poorer survival rate
than those in non-cluster 2 (mean, 13.4 vs. 69.6 month).
Moreover, a Cox regression analysis performed on the pathol-
ogy-oriented variables (Table S11) revealed that cluster 2
significantly and independently correlated with risk for poor
prognosis, even after correction for confounding factors
(P=0.022). These results indicate that miRNA-21 has potential
as a predictor of poor prognosis.
Discussion
In this study, we demonstrate the usefulness and accuracy of
sequencing in genetic research of the human liver cells by
detecting minute alterations in the sequence leading to the
discovery and identification of novel miRNAs, with differential
manifestations between malignant and benign cases. One of the
Figure 5. Gene ontology (GO) term comparison of aberrantly expressed miRNA targets. The predicted gene targets for aberrantly
expressed miRNAs (miR-21, miR-34a, and miR-122) were compared to GO terms under the categories of ‘biological process,’ ‘molecular function,’ and
‘cellular component.’ The figure shows those terms that are overrepresented in the predicted gene targets of the miRNAs compared with all the
Ensembl genes. All values are classified by their significance; the cells marked ‘‘a’’ (P,0.001) indicate that a miRNA specifically targets genes in that
GO functional class.
doi:10.1371/journal.pone.0015304.g005
Figure 4. Quantitative expression profiles of miRNA in the liver. (A) Clustering of the miRNA profiles of 53 liver samples. Clustering analysis
was performed with cloned mature miRNAs. Mature miRNAs that were expressed in fewer than 25% of the samples were not subjected to analysis.
The samples are listed in columns, and the miRNAs are listed in rows. Samples of HCC origin are shown in blue and ANL in yellow at the bottom of
the array. The HCC-derived samples generally cluster together in clusters 1 and 2. A sample number with an asterisk indicates a case of historical
infection with HBV. (B) Expression levels of miR-21 (blue) and miR-122 (green) in the liver. (C) Example of how the clustering profile changes when
one does not consider modified forms. Here is a clustering analysis when one does not consider modified miR-503.
doi:10.1371/journal.pone.0015304.g004
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transcription research is that sequencing is a time-consuming
procedure. And an important consideration for the discovery of
miRNA by sequencing is the difficultly in identifying miRNAs that
are expressed at low levels, at highly specific stages or in rare cell
types. Moreover, a serious problem is that some miRNAs are
difficult to profile precisely due to their physical properties or post-
transcriptional modifications, such as RNA editing. [29,30]I n
principle, these limitations can be overcome by extensive
sequencing of small RNA libraries from a broad range of samples.
For differential display, the sequencing-based method has the
theoretical advantage in that it has the capability to discover and
detect novel miRNAs. Based on our sequence variability results,
especially with regard to RNA modifications, the accuracy of the
sequence-based method is expected to be superior to that of the
hybridization-based method. For the prediction of novel miRNAs,
methods that rely on phylogenetic conservation of the structure
and sequence of a miRNA cannot predict nonconserved genes. To
overcome this problem, we made use of a computational approach
for structural conservation criteria using the thermodynamic
stability and intrinsic structural features of miRNAs. In clinics,
pathologists often meet difficult situations in which they cannot
clearly tell whether the tissue specimens they are observing are
malignant or benign. Thus, in our opinion, using some miRNAs as
a tumor marker would help clinicians to clearly determine whether
that tissue is cancerous. As shown in Fig. 4, miRNA sequences
followed by bioinformatics have greater power than individual
miRNAs or other clinic-pathological variables for the detection of
high risk patients’ groups with poor prognoses. There is currently
little data available as to how we can use each miRNA to predict
high risk groups; however, additional future miRNA work and
data accumulation will elucidate such criteria. And further
Figure 6. Potential application of sequencing-based miRNA clustering for the detection of clinical biomarkers. (A) Distinguishing HCC
from adjacent normal liver using miRNA. This figure shows the receiver-operating-characteristic curve for using various cut-off points (indicatedb y
arrows) of hsa-miR-21, has-miR-122 and has-miR34a. From the area under the curves, hsa-miR-21 and has-miR-122 are potential biomarkers for
prediction of HCC. The true-positives (sensitivity) and false-positives (1-specificity), and the area under the receiver-operating-characteristic curve
were comparatively analyzed. (B) Potential of sequencing-base miRNA clustering to detect predictive biomarkers for clinical course. The patients were
divided into two groups according to the clustering analysis (cluster-2, n=5; non-cluster-2, n=17) (See Figure 4). The Kaplan-Meier method was used
to determine the recurrence (left) and overall survival (right), and the log-rank test was used to compare the rates between the groups.
doi:10.1371/journal.pone.0015304.g006
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e15304investigation is warranted to clarify the mechanism of aberrant
expression of miRNAs in cancer and its participation in
carcinogenesis. Nevertheless, these findings show that sequence-
based miRNA profiling has potential for the confirmation of
precise miRNA dynamics in a specific disease. In addition, it will
increase our understanding of the mechanisms and factors
involved in human liver cancer.
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and light-gray (60–79%). The gray colorations indicate the minus
or plus position of the registered sequence. Note that there are
particular modified patterns according to the particular nucleo-
tide.
(DOC)
Table S8 Results of the SAM and Student’s t-test.
(DOC)
Table S9 Discriminating HCC from adjacent normal
liver using miRNA. The true-positives (sensitivity) and false-
positives (1-specificity), together with the positive predictive values,
negative predictive values, likelihood ratio for positive predictive
value, negative predictive value, likelihood ratio for positive
predictive value, and accuracy at various cut-off points are listed.
(DOC)
Table S10 Analysis of the association between the
postoperative clinical course and variables. The postop-
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